secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001104659-24-062528
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent BioPharma appoints John Hohneker, M.D., to Board of Directors
----------------------------------------------------------------------

- John Hohneker, M.D., appointed to Board of Directors effective May 16, 2024 as Class II Director.
- Dr. Hohneker most recently served as President & CEO of Anokion SA, and previously led R&D at Forma Therapeutics.
- He held senior roles at Novartis for 14 years, including SVP and Global Head of Development, Immunology and Dermatology.
- Current board seats: Carisma Therapeutics (CARM), Curis (CRIS), Sonata Therapeutics, and Trishula Therapeutics.
- Received initial non-qualified stock option with fair value $352,500 vesting over three years; annual cash retainer $45,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924062528/0001104659-24-062528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465924062528/tm2414720d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-062528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer